A Single-centre, Randomized, Double-blind (Sponsor Open), Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2983559, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Participants
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2018
At a glance
- Drugs GSK-2983559 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 02 Aug 2018 Planned End Date changed from 22 Apr 2019 to 16 Sep 2019.
- 02 Aug 2018 Planned primary completion date changed from 22 Apr 2019 to 16 Sep 2019.